🏛️ Verified NIH Record • Updated 2026-05-26
A Nasal Treatment for COVID-19 (NCT05799521)
A Novel Nasal Treatment for COVID-19
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Indiana University
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to test an investigational new inhaled medication called Optate.
Who can join: Review the eligibility criteria below.
Location: Riley Hospital for Children — Indianapolis, Indiana
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Riley Hospital for Children — Indianapolis, Indiana
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COVID-19
- COVID-19 and Cancer Consortium Registry — Nashville, Tennessee
- Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients — Sacramento, California
- COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE) — Bethesda, Maryland
- Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans — Baltimore, Maryland
- Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings — Calgary, Alberta
Explore by condition: All COVID-19 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.